Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2025
Document and Entity Information [Abstract]
Document Type	DEF 14A
Entity Registrant Name	NATERA, INC.
Entity Central Index Key	0001604821
Amendment Flag	false

Pay vs Performance Disclosure - USD ($)

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Pay vs Performance Disclosure

Pay vs Performance Disclosure, Table


														Value of Initial Fixed $100
														Investment Based On:
																	Peer Group
								Average									Total
								Summary			Average						Stockholder
		Summary						Compensation			Compensation						Return
		Compensation			Compensation			Table Total			Actually Paid			Total			(Nasdaq
		Table Total			Actually Paid			for Non-PEO			to Non-PEO			Stockholder			Biotechnology			Net Income			Total Revenue
Year		for PEO⁽¹⁾			to PEO⁽²⁾			NEOs⁽³⁾			NEOs⁽⁴⁾			Return⁽⁵⁾			Index)⁽⁶⁾			(in thousands)⁽⁷⁾			(in thousands)⁽⁸⁾
2025		$	14,957,319		$	60,786,055		$	6,790,799		$	30,070,870		$	230.19		$	124.75		$	(208,160)		$	2,306,113
2024		$	13,032,674		$	95,390,804		$	6,124,794		$	46,461,399		$	159.06		$	93.49		$	(190,426)		$	1,696,911
2023		$	12,727,887		$	32,772,214		$	4,882,630		$	12,994,682		$	62.94		$	94.03		$	(434,801)		$	1,082,571
2022		$	8,246,281		$	(10,478,887)		$	4,548,786		$	(4,682,784)		$	40.36		$	89.90		$	(547,799)		$	820,222
2021		$	23,343,147		$	17,842,930		$	8,415,636		$	7,334,133		$	93.84		$	100.02		$	(471,716)		$	625,486

(1)	Our PEO for each year reported is Steven Chapman, our Chief Executive Officer. The dollar amounts reported in this column are the amounts of total compensation reported for Mr. Chapman in the “Total” column of the Summary Compensation Table in the applicable fiscal year.

(2)	In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid to our PEO during fiscal years 2025 and 2024, which consisted solely of adjustments to the PEO’s equity awards:


Description of Adjustment		2025		2024
Summary Compensation Table – Total Compensation		$	14,957,319	$	13,032,674
- grant date fair value of option awards and stock awards granted in the covered fiscal year		$	(12,979,558)	$	(11,284,474)
+ fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year		$	25,210,438	$	40,945,878
+ change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years		$	29,506,263	$	44,724,070
+ fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year		$	0	$	833,838
+ change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year		$	4,091,593	$	7,138,818
- fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year		$	0	$	0
+ dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation		$	0	$	0
Total Equity Adjustments (subtotal)*		$	45,828,736	$	82,358,130
Compensation Actually Paid		$	60,786,055	$	95,390,804

(3)	The non-PEO NEOs for each year reported are as follows:

For 2025: Michael Brophy, John Fesko, Solomon Moshkevich, and Matthew Rabinowitz

For 2024: Michael Brophy, John Fesko, Solomon Moshkevich, and Matthew Rabinowitz

For 2023: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

For 2022: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

For 2021: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

The dollar amounts reported in this column represent the average of the amounts reported for the non-PEO NEOs in the “Total” column of the Summary Compensation Table in the applicable fiscal year.

(4)	In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid on average to our non-PEO NEOs during fiscal years 2025 and 2024, which consisted solely of adjustments to the non-PEO NEOs’ equity awards:


Description of Adjustment		2025		2024
Summary Compensation Table – Total Compensation		$	6,790,799	$	6,124,794
- grant date fair value of option awards and stock awards granted in the covered fiscal year		$	(5,892,939)	$	(5,334,407)
+ fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year		$	11,445,966	$	19,355,974
+ change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years		$	16,134,010	$	23,293,949
+ fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year		$	0	$	383,798
+ change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year		$	1,593,034	$	2,637,291
- fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year		$	0	$	0
+ dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation		$	0	$	0
Total Equity Adjustments (subtotal)*		$	23,280,071	$	40,336,605
Compensation Actually Paid		$	30,070,870	$	46,461,399

(5)

Cumulative total stockholder return on our shares of common stock from December 31, 2020 through December 31, 2021, December 31, 2022, December 31, 2023, December 31, 2024, and December 31, 2025, respectively. Assumes the investment of $100 on December 31, 2020 in our shares of common stock and assumes the reinvestment of dividends, if any, although dividends have never been declared on our shares of common stock.

(6)

Cumulative total stockholder return on the NASDAQ Biotechnology Index from December 31, 2020 through December 31, 2021, December 31, 2022, December 31, 2023, December 31, 2024, and December 31, 2025, respectively. Assumes the investment of $100 on December 31, 2020 in the NASDAQ Biotechnology Index and assumes the reinvestment of dividends.

(7)	The dollar amounts reported represent the amount of net income reflected in our audited financial statements for the applicable year.

(8)	The dollar amounts reported represent the amount of total revenue reflected in our audited financial statements for the applicable year.

Company Selected Measure Name

Total Revenue

Named Executive Officers, Footnote

(1)	Our PEO for each year reported is Steven Chapman, our Chief Executive Officer. The dollar amounts reported in this column are the amounts of total compensation reported for Mr. Chapman in the “Total” column of the Summary Compensation Table in the applicable fiscal year.

(3)	The non-PEO NEOs for each year reported are as follows:

For 2025: Michael Brophy, John Fesko, Solomon Moshkevich, and Matthew Rabinowitz

For 2024: Michael Brophy, John Fesko, Solomon Moshkevich, and Matthew Rabinowitz

For 2023: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

For 2022: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

For 2021: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

Peer Group Issuers, Footnote

(6)

PEO Total Compensation Amount

$ 14,957,319

$ 13,032,674

$ 12,727,887

$ 8,246,281

$ 23,343,147

PEO Actually Paid Compensation Amount

$ 60,786,055

95,390,804

32,772,214

(10,478,887)

17,842,930

Adjustment To PEO Compensation, Footnote

(2)	In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid to our PEO during fiscal years 2025 and 2024, which consisted solely of adjustments to the PEO’s equity awards:


Description of Adjustment		2025		2024
Summary Compensation Table – Total Compensation		$	14,957,319	$	13,032,674
- grant date fair value of option awards and stock awards granted in the covered fiscal year		$	(12,979,558)	$	(11,284,474)
+ fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year		$	25,210,438	$	40,945,878
+ change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years		$	29,506,263	$	44,724,070
+ fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year		$	0	$	833,838
+ change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year		$	4,091,593	$	7,138,818
- fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year		$	0	$	0
+ dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation		$	0	$	0
Total Equity Adjustments (subtotal)*		$	45,828,736	$	82,358,130
Compensation Actually Paid		$	60,786,055	$	95,390,804

Non-PEO NEO Average Total Compensation Amount

$ 6,790,799

6,124,794

4,882,630

4,548,786

8,415,636

Non-PEO NEO Average Compensation Actually Paid Amount

$ 30,070,870

46,461,399

12,994,682

(4,682,784)

7,334,133

Adjustment to Non-PEO NEO Compensation Footnote

(4)	In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid on average to our non-PEO NEOs during fiscal years 2025 and 2024, which consisted solely of adjustments to the non-PEO NEOs’ equity awards:


Description of Adjustment		2025		2024
Summary Compensation Table – Total Compensation		$	6,790,799	$	6,124,794
- grant date fair value of option awards and stock awards granted in the covered fiscal year		$	(5,892,939)	$	(5,334,407)
+ fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year		$	11,445,966	$	19,355,974
+ change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years		$	16,134,010	$	23,293,949
+ fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year		$	0	$	383,798
+ change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year		$	1,593,034	$	2,637,291
- fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year		$	0	$	0
+ dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation		$	0	$	0
Total Equity Adjustments (subtotal)*		$	23,280,071	$	40,336,605
Compensation Actually Paid		$	30,070,870	$	46,461,399

Tabular List, Table

Most Important Performance Measures

For 2025, the most important performance measures used to inform our executive compensation decisions included the following:

●

Total revenue

●

Product gross margin

●

Operating cash flow

Total Shareholder Return Amount

$ 230.19

159.06

62.94

40.36

93.84

Peer Group Total Shareholder Return Amount

124.75

93.49

94.03

89.9

100.02

Net Income (Loss)

$ (208,160,000)

$ (190,426,000)

$ (434,801,000)

$ (547,799,000)

$ (471,716,000)

Company Selected Measure Amount

2,306,113,000

1,696,911,000

1,082,571,000

820,222,000

625,486,000

PEO Name

Steven Chapman

Measure:: 1

Pay vs Performance Disclosure

Name

Total revenue

Non-GAAP Measure Description

(8)	The dollar amounts reported represent the amount of total revenue reflected in our audited financial statements for the applicable year.

Measure:: 2

Pay vs Performance Disclosure

Name

Product gross margin

Measure:: 3

Pay vs Performance Disclosure

Name

Operating cash flow

PEO | Equity Awards Adjustments

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ 45,828,736

$ 82,358,130

PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(12,979,558)

(11,284,474)

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

25,210,438

40,945,878

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

29,506,263

44,724,070

PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

833,838

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

4,091,593

7,138,818

PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

Non-PEO NEO | Equity Awards Adjustments

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

23,280,071

40,336,605

Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(5,892,939)

(5,334,407)

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

11,445,966

19,355,974

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

16,134,010

23,293,949

Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

383,798

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

1,593,034

2,637,291

Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ 0

Award Timing Disclosure	12 Months Ended
Award Timing Disclosure	Dec. 31, 2025
Award Timing Disclosures [Line Items]
Award Timing MNPI Disclosure	Our human capital committee does not grant stock options to employees, including executive officers, during periods in which there is material nonpublic information about our Company, including (1) outside a “trading window” established in connection with the public release of earnings information under our Insider Trading Policy or (2) at any time during the four business days prior to or the one business day following the filing of our periodic reports or the filing or furnishing of a Form 8-K that discloses material nonpublic information. Further, during 2025, our human capital committee did not grant any stock options to our employees, executive officers, or other service providers. The human capital committee does not take material nonpublic information into account when determining the timing and terms of equity awards. Equity awards may occasionally be awarded on an off-cycle basis, including to new hires. The Company has not timed the disclosure of material nonpublic information to affect the value of executive compensation. Under the terms of our Equity Plan, pursuant to which new equity awards are granted, the exercise price of any option to purchase shares of our common stock awarded under the Equity Plan must be equal to at least 100% of the fair market value of our common stock (which is determined based on the closing sales price of our common stock on the Nasdaq Global Select Market) on the date of grant. Grants of equity awards to our executive officers are generally determined and approved at our pre-scheduled quarterly human capital committee meetings whenever practicable, and the awards are granted in accordance with our equity grant policies and processes. In addition, our human capital committee approves the annual equity refresh grants, including performance-based awards, in the first quarter of each year. However, our human capital committee may otherwise approve the grant of equity awards outside of a pre-scheduled meeting in connection with a new hire, promotion, and other circumstances where our human capital committee deems it appropriate to make such grants.
Award Timing Method	Our human capital committee does not grant stock options to employees, including executive officers, during periods in which there is material nonpublic information about our Company, including (1) outside a “trading window” established in connection with the public release of earnings information under our Insider Trading Policy or (2) at any time during the four business days prior to or the one business day following the filing of our periodic reports or the filing or furnishing of a Form 8-K that discloses material nonpublic information. Further, during 2025, our human capital committee did not grant any stock options to our employees, executive officers, or other service providers. The human capital committee does not take material nonpublic information into account when determining the timing and terms of equity awards.
Award Timing Predetermined	true
Award Timing MNPI Considered	false
Award Timing, How MNPI Considered	Our human capital committee does not grant stock options to employees, including executive officers, during periods in which there is material nonpublic information about our Company, including (1) outside a “trading window” established in connection with the public release of earnings information under our Insider Trading Policy or (2) at any time during the four business days prior to or the one business day following the filing of our periodic reports or the filing or furnishing of a Form 8-K that discloses material nonpublic information. Further, during 2025, our human capital committee did not grant any stock options to our employees, executive officers, or other service providers. The human capital committee does not take material nonpublic information into account when determining the timing and terms of equity awards. Equity awards may occasionally be awarded on an off-cycle basis, including to new hires. The Company has not timed the disclosure of material nonpublic information to affect the value of executive compensation.
MNPI Disclosure Timed for Compensation Value	false

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true